Information Provided By:
Fly News Breaks for June 23, 2017
PTLA
Jun 23, 2017 | 08:47 EDT
After examining 22 cases over the last three years where a PDUFA date for a drug's approval fell on a weekend or holiday, Citi analyst Yigal Nochomovitz found a "strong bias" for the FDA to issue its decision prior to, rather than on or after, the deadline date. Given that the PDUFA date for Portola's betrixaban falls on Saturday, June 24, Nochomovitz said he expects the FDA to issue its decision on betrixaban today, June 23. The analyst, who sees a high probability of approval, keeps a Buy rating on Portola shares.
News For PTLA From the Last 2 Days
There are no results for your query PTLA
I agree to the thefly.com's disclaimer & terms of use
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.